Humira’s PMS ends on August, triggering biosimilar development competition
The domestic PMS(post marketing surveillance) of Humira(adalimumab, Abbvie), a rheumatoid arthritis treatment having the globally KRW 16 trillion sales market, will end this August.
Since the development of Humira biosimilars is so active, the competition for the exclusive sales rights under th...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
